Adipose-Derived Stromal Cells (ASC's) for Pressure Ulcers
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This pilot study of 12 patients will test the safety and efficacy of applying autologous,
adipose-derived stromal cells (ASCs), uncultured, on a Stage III or IV pressure ulcer or
diabetic foot ulcers. Patients will undergo a minimal risk liposuction procedure to withdraw
50-100 cc of adipose tissue. The tissue would be processed to extract the stromal layer of
cells that contain stem cells. The ASCs would be injected into a fibrin sealant to be applied
to the wound. Patients would be followed for 6 weeks to assess wound healing and tolerance of
the treatment.